Clinical Trial Update: Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial investigates adding lenalidomide or vorinostat to azacitidine in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome
• Myelodysplastic Syndrome Acute Myeloid Leukemia
• Myelodysplastic Syndrome with Excess Blasts
• Myelodysplastic Syndrome with Excess Blasts-1
• Myelomonocytic Leukemia
• Myelomonocytic Leukemia-1
• Myelomonocytic Leukemia-2

Drugs mentioned

• Revlimid (lenalidomide)
• VIDAZA (AZACITIDINE)
• Zolinza (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1 | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2016-03-22